About the Company
AIM ImmunoTech Inc., formerly known as Hemispherx Biopharma Inc., is a biopharmaceutical company based in Ocala, Florida that is focused on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. Founded in 1990, the company has twenty-three employees. The company has created an immunomodulatory double stranded RNA drug called Ampligen. It is also developing Ampligen to use as a treatment for multiple cancer tumor types, COVID-19 and chronic fatigue syndrome.
Exchange
NYSE
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on AIM ImmunoTech Inc.
AIM ImmunoTech Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Continued progress across pipeline programs with focus on pancreatic cancer Mid-year report of Ampligen® (rintatolimod) in ...
AIM ImmunoTech Builds Positive Momentum and Reiterates Focus on Driving Ampligen® Clinical Development Toward Pancreatic Cancer Approval
Primary focus on pancreatic cancer Mid-year report of Ampligen® (rintatolimod) in combination with AstraZeneca’s Imfinzi® (durvalumab) for the treatment of pancreatic cancer demonstrates positive ...
AIM ImmunoTech Inc. (AIM) Q1 2024 Earnings Call Transcript
AIM ImmunoTech Inc. (NYSE: AIM) Q1 2024 Earnings Conference Call May 16, 2024 8:30 AM ET Company Participants Thomas Equels - CEO Christopher McAleer - Scientific Officer Conference Call Participants ...
AIM ImmunoTech Inc. Shares Key Updates on Clinical Trials and Future ...
AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19.
AIM ImmunoTech to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech
PM ETOCALA, Fla., Aug. 14, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today ...
AIM ImmunoTech Inc. Granted Patent for Ampligen® in Treatment ... - Nasdaq
AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19.
AIM ImmunoTech Inc. (AMEX:AIM) Q4 2023 Earnings Call Transcript
AIM ImmunoTech Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Hello.
Delaware Supreme Court’s Kellner v. AIM Immunotech Inc. Decision ...
AIM Immunotech Inc.), in which AIM largely prevailed, with the court upholding the Board’s decision to reject the nomination notice.
AIM ImmunoTech Inc. (AIM) Q3 2024 Earnings Call Transcript
AIM ImmunoTech Inc. (AIM) Q3 2024 Earnings Call Transcript Nov. 15, 2024 10:32 AM ET AIM ImmunoTech Inc. (AIM) Stock AIM SA Transcripts 154.93K Follower s ...
AIM ImmunoTech Inc. (AMEX:AIM) Q1 2024 Earnings Call Transcript
AIM ImmunoTech Inc. misses on earnings expectations. Reported EPS is $-0.12 EPS, expectations were $-0.11. Operator: Hello, and welcome to the AIM ImmunoTech First Quarter 2024 Update Conference ...
Similar Companies
Loading the latest forecasts...